ATNF vs. NBSE, INM, HSTO, PBLA, GRI, PRFX, GLMD, BPTH, LSDI, and CMRA
Should you be buying 180 Life Sciences stock or one of its competitors? The main competitors of 180 Life Sciences include NeuBase Therapeutics (NBSE), InMed Pharmaceuticals (INM), Histogen (HSTO), Panbela Therapeutics (PBLA), GRI Bio (GRI), PainReform (PRFX), Galmed Pharmaceuticals (GLMD), Bio-Path (BPTH), Lucy Scientific Discovery (LSDI), and Comera Life Sciences (CMRA). These companies are all part of the "pharmaceutical preparations" industry.
NeuBase Therapeutics (NASDAQ:NBSE) and 180 Life Sciences (NASDAQ:ATNF) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk, profitability, media sentiment and community ranking.
180 Life Sciences' return on equity of -99.74% beat NeuBase Therapeutics' return on equity.
In the previous week, NeuBase Therapeutics and NeuBase Therapeutics both had 1 articles in the media. 180 Life Sciences' average media sentiment score of 0.00 equaled NeuBase Therapeutics'average media sentiment score.
NeuBase Therapeutics has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500. Comparatively, 180 Life Sciences has a beta of 0.44, meaning that its share price is 56% less volatile than the S&P 500.
12.4% of NeuBase Therapeutics shares are owned by institutional investors. Comparatively, 4.1% of 180 Life Sciences shares are owned by institutional investors. 13.9% of NeuBase Therapeutics shares are owned by insiders. Comparatively, 4.1% of 180 Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
NeuBase Therapeutics received 47 more outperform votes than 180 Life Sciences when rated by MarketBeat users. However, 66.67% of users gave 180 Life Sciences an outperform vote while only 60.49% of users gave NeuBase Therapeutics an outperform vote.
Summary
NeuBase Therapeutics beats 180 Life Sciences on 7 of the 8 factors compared between the two stocks.
Get 180 Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATNF and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ATNF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
180 Life Sciences Competitors List
Related Companies and Tools
